These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

435 related items for PubMed ID: 31820121

  • 1. Efficacy of risedronate with cholecalciferol on bone mineral density in Korean patients with osteoporosis.
    Park SY, Kang MI, Park HM, Rhee Y, Moon SH, Yoon HK, Koh JM, Chang JS, Kim IJ, Won YY, Park YS, Choi H, Shin CS, Yoon TR, Yun SC, Chung HY, IDEAL Trial Investigators.
    Arch Osteoporos; 2019 Dec 09; 15(1):3. PubMed ID: 31820121
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
    Chung HY, Chin SO, Kang MI, Koh JM, Moon SH, Yoon BK, Yoon HK, Chung YS, Park HM.
    Clin Endocrinol (Oxf); 2011 Jun 09; 74(6):699-704. PubMed ID: 21521310
    [Abstract] [Full Text] [Related]

  • 3. Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
    Chung HY, Koo J, Kwon SK, Kang MI, Moon SH, Park JY, Shin CS, Yoon BK, Yoon HK, Chang JS, Chung YS, Park HM.
    Clin Interv Aging; 2013 Jun 09; 8():597-603. PubMed ID: 23761968
    [Abstract] [Full Text] [Related]

  • 4. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF.
    Arthritis Rheumatol; 2019 Jul 09; 71(7):1174-1184. PubMed ID: 30816640
    [Abstract] [Full Text] [Related]

  • 5. Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.
    Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ.
    J Bone Miner Res; 2004 Aug 09; 19(8):1221-30. PubMed ID: 15231008
    [Abstract] [Full Text] [Related]

  • 6. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar 09; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 7. Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
    Soo I, Siffledeen J, Siminoski K, McQueen B, Fedorak RN.
    J Crohns Colitis; 2012 Aug 09; 6(7):777-86. PubMed ID: 22398088
    [Abstract] [Full Text] [Related]

  • 8. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun 09; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 9. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
    Coin A, Veronese N, Bolzetta F, De Rui M, Manzato E, Sergi G.
    Panminerva Med; 2012 Dec 09; 54(4):277-82. PubMed ID: 23123579
    [Abstract] [Full Text] [Related]

  • 10. Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
    Takakuwa M, Iwamoto J, Itabashi K.
    Clin Drug Investig; 2012 Feb 01; 32(2):121-9. PubMed ID: 22185631
    [Abstract] [Full Text] [Related]

  • 11. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K, Harigane K, Kusayama Y, Tezuka T, Choe H, Inaba Y, Saito T.
    Osteoporos Int; 2018 Jul 01; 29(7):1637-1642. PubMed ID: 29574518
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of risedronate in Japanese male patients with primary osteoporosis.
    Majima T, Shimatsu A, Komatsu Y, Satoh N, Fukao A, Ninomiya K, Matsumura T, Nakao K.
    Intern Med; 2008 Jul 01; 47(8):717-23. PubMed ID: 18421187
    [Abstract] [Full Text] [Related]

  • 13. Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
    Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T.
    Bone; 2014 Feb 01; 59():44-52. PubMed ID: 24184313
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
    Ishida T, Yoshida S, Kimura Y, Fujiki Y, Kotani T, Takeuchi T, Makino S, Arawaka S.
    Lupus; 2018 Sep 01; 27(10):1636-1643. PubMed ID: 29954283
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou CL, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P.
    Osteoporos Int; 2013 Jan 01; 24(1):293-9. PubMed ID: 22752050
    [Abstract] [Full Text] [Related]

  • 16. Response of bone mineral density to once-weekly administration of risedronate.
    Gordon MS, Gordon MB.
    Endocr Pract; 2002 Jan 01; 8(3):202-7. PubMed ID: 12113633
    [Abstract] [Full Text] [Related]

  • 17. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.
    J Bone Miner Res; 2009 Apr 01; 24(4):719-25. PubMed ID: 19049326
    [Abstract] [Full Text] [Related]

  • 18. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
    Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R, Zanchetta J, Olszynski WP, Recker RR, McClung MR.
    Osteoporos Int; 2008 Jul 01; 19(7):1039-45. PubMed ID: 18087660
    [Abstract] [Full Text] [Related]

  • 19. Preoperative bone health assessment and optimization in spine surgery.
    Anderson PA, Kadri A, Hare KJ, Binkley N.
    Neurosurg Focus; 2020 Aug 01; 49(2):E2. PubMed ID: 32738805
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with risedronate and teriparatide in male osteoporosis.
    Walker MD, Cusano NE, Sliney J, Romano M, Zhang C, McMahon DJ, Bilezikian JP.
    Endocrine; 2013 Aug 01; 44(1):237-46. PubMed ID: 23099796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.